CNBC Television published this video item, entitled “Equity analyst on why he remains a ‘skeptic’ on Biogen’s new Alzheimer’s drug” – below is their description.
The Food and Drug Administration on Monday approved Biogen’s Alzheimer’s disease drug aducanumab, making it the first medication cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer’s and the first new medicine for the disease in nearly two decades. The Massachusetts-based biotechnology company said Monday that aducanumab’s list price is $56,000 per year; $4,312 per infusion. Kevin Huang, senior equity analyst covering biotech and medtech at CFRA, joined “Squawk Box” on Tuesday to discuss.
CNBC Television YouTube Channel
Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.